These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19022324)

  • 1. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.
    Simon JK; Wahid R; Maciel M; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Vaccine; 2009 Jan; 27(4):565-72. PubMed ID: 19022324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.
    Li A; Kärnell A; Huan PT; Cam PD; Minh NB; Trâm LN; Quy NP; Trach DD; Karlsson K; Lindberg G
    Vaccine; 1993; 11(2):180-9. PubMed ID: 8438616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.
    Wahid R; Simon JK; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Clin Immunol; 2013 Jul; 148(1):35-43. PubMed ID: 23649043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.
    Simon JK; Maciel M; Weld ED; Wahid R; Pasetti MF; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Clin Immunol; 2011 May; 139(2):185-92. PubMed ID: 21388888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys.
    Kärnell A; Cam PD; Verma N; Lindberg AA
    Vaccine; 1993; 11(8):830-6. PubMed ID: 8356844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
    Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
    Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers.
    Li A; Pál T; Forsum U; Lindberg AA
    Vaccine; 1992; 10(6):395-404. PubMed ID: 1598788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.
    Noriega FR; Losonsky G; Wang JY; Formal SB; Levine MM
    Infect Immun; 1996 Jan; 64(1):23-7. PubMed ID: 8557344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
    Chakraborty S; Harro C; DeNearing B; Bream J; Bauers N; Dally L; Flores J; Van de Verg L; Sack DA; Walker R
    Clin Vaccine Immunol; 2016 Apr; 23(4):315-25. PubMed ID: 26865592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulated Delayed
    Su H; Liu Q; Wang S; Curtiss R; Kong Q
    Theranostics; 2019; 9(12):3565-3579. PubMed ID: 31281498
    [No Abstract]   [Full Text] [Related]  

  • 14. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes.
    Kärnell A; Sweiha H; Lindberg AA
    Vaccine; 1992; 10(3):167-74. PubMed ID: 1557932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers.
    Kärnell A; Li A; Zhao CR; Karlsson K; Nguyen BM; Lindberg AA
    Vaccine; 1995 Jan; 13(1):88-99. PubMed ID: 7762285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
    Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
    Orr N; Robin G; Cohen D; Arnon R; Lowell GH
    Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.
    Coster TS; Hoge CW; VanDeVerg LL; Hartman AB; Oaks EV; Venkatesan MM; Cohen D; Robin G; Fontaine-Thompson A; Sansonetti PJ; Hale TL
    Infect Immun; 1999 Jul; 67(7):3437-43. PubMed ID: 10377124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
    Kotloff KL; Losonsky GA; Nataro JP; Wasserman SS; Hale TL; Taylor DN; Newland JW; Sadoff JC; Formal SB; Levine MM
    Vaccine; 1995 Apr; 13(5):495-502. PubMed ID: 7639017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.